Experienced in Acquired Amegakaryocytic Thrombocytopenia

Polina Y. Stepensky

Hadassah Ein Kerem
Jerusalem, JM, IL 
Experienced in Acquired Amegakaryocytic Thrombocytopenia
Hadassah Ein Kerem
Jerusalem, JM, IL 
OverviewLocationsClinical Research

Overview

Polina Stepensky practices in Jerusalem, Israel. Ms. Stepensky is rated as an Experienced expert by MediFind in the treatment of Acquired Amegakaryocytic Thrombocytopenia. Her top areas of expertise are Osteopetrosis, Infantile Neutropenia, Adenosine Deaminase Deficiency, Osteosclerosis Autosomal Dominant, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 171 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Acquired Amegakaryocytic Thrombocytopenia.

Gender
Female

Locations

Hadassah Ein Kerem
Jerusalem, JM, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An Open Label, Single Arm, Multicentre, Proof of Concept, Phase 2 Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After Allogeneic Hematopoietic Stem Cell Transplantation
An Open Label, Single Arm, Multicentre, Proof of Concept, Phase 2 Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: December 28, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2a, Open-label, Multicenter, Study to Evaluate the Pharmacokinetic (PK), Safety and Efficacy of Multiple Doses of Cannabidiol for the Prevention of aGVHD After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
A Phase 2a, Open-label, Multicenter, Study to Evaluate the Pharmacokinetic (PK), Safety and Efficacy of Multiple Doses of Cannabidiol for the Prevention of aGVHD After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Enrollment Status: Unknown
Publish Date: September 01, 2021
Intervention Type: Drug
Study Drug: Cannabidiol
Study Phase: Phase 2
View 1 Less Clinical Trial

171 Total Publications

Once-Daily Versus Four-Times-Daily Intravenous Busulfan with Therapeutic Drug Monitoring as Conditioning for Hematopoietic Cell Transplantation in Children.
Once-Daily Versus Four-Times-Daily Intravenous Busulfan with Therapeutic Drug Monitoring as Conditioning for Hematopoietic Cell Transplantation in Children.
Journal: Pharmaceutics
Published: July 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Stepensky's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 16 Advanced Conditions
View All 52 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile